Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 1 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Gastrointestinal 4Endocrine 4

Conditions

Colorectal Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 4Rectal Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 4Esophageal Neoplasms 4Diarrhea 4Weight Loss 3Pancreatic Neoplasms 3Neuroendocrine Tumors 3Colonic Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Malnutrition 2Duodenal Neoplasms 2Vulvar Neoplasms 1Vomiting 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatitis 1Pancreatic Neuroendocrine Tumor G2 1Pancreatic Intraductal Neoplasms 1Nutrition Disorders 1Neoplastic Cells, Circulating 1Nausea 1Liver Neoplasms 1Intestinal Obstruction 1Insulin Resistance 1

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Octreotide × Gastrointestinal × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡